| Cash Flow | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 370,400 | 178,000 | 469,999 | 296,714 |
| Depreciation, depletion, and amortization | 241,100 | 119,400 | 353,866 | 227,953 |
| Deferred income taxes | -100 | 0 | -23,787 | -22,085 |
| Share-based compensation expense | 33,100 | 11,900 | 47,606 | 32,272 |
| Loss on the disposal of property, plant, equipment, and intangibles, net | -100 | 0 | -3,004 | -2,699 |
| Loss (gain) on sale of businesses and equity investment, net | -300 | 0 | 4,473 | 4,458 |
| Amortization of inventory fair value adjustments | - | - | 0 | - |
| Other items | -13,200 | -14,500 | 7,156 | -586 |
| Accounts receivable, net | -113,900 | -119,200 | -79,295 | -82,506 |
| Inventories, net | 60,700 | 42,500 | 727 | 18,677 |
| Other current assets | -25,500 | -18,900 | 18,353 | -8,565 |
| Accounts payable | 23,000 | 9,800 | -7,504 | -16,261 |
| Accruals and other, net | -52,100 | -9,200 | -4,464 | -35,346 |
| Net cash provided by operating activities | 707,800 | 420,000 | 887,306 | 554,468 |
| Purchases of property, plant, equipment, and intangibles, net | 180,100 | 93,600 | 299,206 | 209,975 |
| Proceeds from the sale of property, plant, equipment, and intangibles | - | 100 | 4 | 0 |
| Proceeds from the sale of businesses | 0 | 0 | 811,434 | 809,919 |
| Purchase of investments | 1,800 | - | - | - |
| Acquisition of businesses, net of cash acquired | 15,000 | 15,000 | 53,659 | 17,467 |
| Net cash used in investing activities | -196,800 | -108,500 | 458,573 | 582,477 |
| Payments on private placement senior notes | 125,000 | 125,000 | 80,000 | - |
| Payments on term loans | 0 | 0 | 638,125 | 638,125 |
| Payments under credit facilities, net | -34,800 | -30,500 | -318,992 | -344,920 |
| Deferred financing fees and debt issuance costs | - | - | 2,316 | - |
| Acquisition related deferred or contingent consideration | 200 | 100 | 266 | 177 |
| Repurchases of ordinary shares | 111,100 | 10,600 | 211,058 | 110,625 |
| Cash dividends paid to ordinary shareholders | 118,100 | 56,200 | 163,869 | 107,673 |
| Payments to noncontrolling interests | - | - | 1,579 | - |
| Contributions from noncontrolling interest holders | 0 | 0 | 2,532 | 2,532 |
| Stock option and other equity transactions, net | 16,900 | 9,300 | 19,380 | 19,092 |
| Net cash used in financing activities | -372,300 | -213,100 | -1,394,293 | -1,179,896 |
| Effect of exchange rate on cash, cash equivalent, restricted cash, and restricted cash equivalent, continuing operation | 8,700 | 9,600 | -3,428 | 8,126 |
| Increase (decrease) in cash and cash equivalents | 147,500 | 108,000 | -51,842 | -34,825 |
| Cash and cash equivalents at beginning of period | 171,700 | 171,700 | 207,020 | 207,020 |
| Cash and cash equivalents at end of period | 319,200 | 279,700 | 155,178 | 172,195 |
STERIS plc (STE)
STERIS plc (STE)